Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;12(4):362-74.
doi: 10.7497/j.issn.2095-3941.2015.0063.

Advances in drug delivery system for platinum agents based combination therapy

Xiang Kang  1 , Hai-Hua Xiao  1 , Hai-Qin Song  1 , Xia-Bin Jing  1 , Le-San Yan  1 , Ruo-Gu Qi  1
Affiliations
Review

Advances in drug delivery system for platinum agents based combination therapy

Xiang Kang et al. Cancer Biol Med. 2015 Dec.

Abstract

Platinum-based anticancer agents are widely used as first-line drugs in cancer chemotherapy for various solid tumors. However, great side effects and occurrence of resistance remain as the major drawbacks for almost all the platinum drugs developed. To conquer these problems, new strategies should be adopted for platinum drug based chemotherapy. Modern nanotechnology has been widely employed in the delivery of various therapeutics and diagnostic. It provides the possibility of targeted delivery of a certain anticancer drug to the tumor site, which could minimize toxicity and optimize the drug efficacy. Here, in this review, we focused on the recent progress in polymer based drug delivery systems for platinum-based combination therapy.

Keywords: Cancer; combination therapy; drug delivery; platinum.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest are disclosed.

Figures

Figure 1
Figure 1
Representative drug combinations of two drug loaded nanoparticles. (A) Combined NC-6003 (epirubicin). (B) NC-4016 (oxaliplatin) micelles.
Figure 2
Figure 2
Combination of two strong cytotoxic agents in one nanoparticle platform. (A) Doxorubicin and cisplatin prodrug were combined in a polymer-caged nanobin. (B) Cisplatin and doxorubicin were combined in dextrin-derivative polymer micelles. (C) Paclitaxel and cisplatin were combined in poly-peptide nanomicelles.
Figure 3
Figure 3
Combination of a cytotoxic platinum agent with a less cytotoxic drug sensitizer ethacrynic acid to minimize the glutathione mediated Pt detoxification. (A) Chemical structure of P(Pt) and P(EA). (B) Schematic illustration of self-assembling P(Pt) and P(EA) into M(EA/Pt) and its intracellular fate. (C) In-vivo evaluation of tumor inhibition effect of M(EA/Pt). (D) In-vivo evaluation of body weight change after treatment of M(EA/Pt).
Figure 4
Figure 4
Combination of two cytotoxic agents in one nanoparticle platform. (A) Polymer-cisplatin (IV) conjugates and polymer-paclitaxel conjugates were mixed to prepare micelles with both cisplatin and paclitaxel for combinational drug delivery. (B) Polymer-cisplatin (IV) conjugates were used to encapsulate docetaxel for combinational drug delivery.
Figure 5
Figure 5
Ratio metric combination of two drugs in a multifunctional Pt(IV) prodrug. (A) Paclitaxel and cisplatin were combined in a Pt(IV) prodrug and encapsulated for drug delivery. (B) Norcantharidin and cisplatin were combined in a Pt(IV) prodrug and conjugated for drug delivery.
See this image and copyright information in PMC

References

    1. Shaili E. Platinum anticancer drugs and photochemotherapeutic agents: recent advances and future developments. Sci Prog 2014;97:20-40. - PMC - PubMed
    1. Available online: http://www.nccn.org/
    1. Abu-Surrah AS, Kettunen M. Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Curr Med Chem 2006;13:1337-1357. - PubMed
    1. Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005;53:3-11. - PubMed
    1. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-2498. - PubMed

LinkOut - more resources